Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T H 1 T-cells

Immune checkpoint inhibitor (ICI)-based cancer therapies cause a variety of cutaneous immune-related adverse events (irAEs) including immunobullous skin eruptions like bullous pemphigoid (BP). However, little is known about the underlying immunopathogenic drivers of these reactions, and understandin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cutaneous pathology 2023-07, Vol.50 (7), p.661-673
Hauptverfasser: Marques-Piubelli, Mario L, Seervai, Riyad N H, Mudaliar, Kumaran M, Ma, Wencai, Milton, Denái R, Wang, Jing, Muhlbauer, Aaron, Parra, Edwin R, Solis, Luisa M, Nagarajan, Priyadharsini, Speiser, Jodi, Hudgens, Courtney, Cho, Woo Cheal, Aung, Phyu P, Patel, Anisha, Pacha, Omar, Nelson, Kelly C, Tetzlaff, Michael T, Amaria, Rodabe N, Torres-Cabala, Carlos A, Prieto, Victor G, Wistuba, Ignacio I, Curry, Jonathan L
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 673
container_issue 7
container_start_page 661
container_title Journal of cutaneous pathology
container_volume 50
creator Marques-Piubelli, Mario L
Seervai, Riyad N H
Mudaliar, Kumaran M
Ma, Wencai
Milton, Denái R
Wang, Jing
Muhlbauer, Aaron
Parra, Edwin R
Solis, Luisa M
Nagarajan, Priyadharsini
Speiser, Jodi
Hudgens, Courtney
Cho, Woo Cheal
Aung, Phyu P
Patel, Anisha
Pacha, Omar
Nelson, Kelly C
Tetzlaff, Michael T
Amaria, Rodabe N
Torres-Cabala, Carlos A
Prieto, Victor G
Wistuba, Ignacio I
Curry, Jonathan L
description Immune checkpoint inhibitor (ICI)-based cancer therapies cause a variety of cutaneous immune-related adverse events (irAEs) including immunobullous skin eruptions like bullous pemphigoid (BP). However, little is known about the underlying immunopathogenic drivers of these reactions, and understanding the unique gene expression profile and immune composition of BP-irAE remains a critical knowledge gap in the field of oncodermatology/oncodermatopathology. BP-irAE (n = 8) and de novo BP control (n = 8) biopsy samples were subjected to gene expression profiling using the NanoString® Technologies nCounter PanCancer Immune Profiling Panel. Multiplex immunofluorescence (mIF) studies using markers for T-cells (CD3 and CD8), T helper 1 (T 1) cells (Tbet), T 2 cells (Gata3), T 17 cells (RORγT), and regulatory T-cells (Tregs; FoxP3) were further evaluated using InForm® image analysis. Compared with de novo BP controls, BP-irAE samples exhibited upregulation of 30 mRNA transcripts (p 
doi_str_mv 10.1111/cup.14442
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_cup_14442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37150813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573-ab4d604d224da826f0b1e6b8892a7a2186b1b2544836dbeab6253e69ea31826c3</originalsourceid><addsrcrecordid>eNo9kbFuFDEQhi0EIpdAwQsgtxRO7LXXt1eiCBKkSGmuX3nt2cPgtS17HeWemxdgLheYZppvvn-kn5BPgl8LnBvb8rVQSnVvyEZozhnvNX9LNlxyyfRu2F6Qy1p_cS70oPv35EJuRc8HITfkzx1EoPCcC9TqU6S5pNkHHw_UREeXFlafAzxTvywtpjm0hKSFaAEBE47VV5pmOrUQUqs0w5J_-kPy7nwBrEAwKzhq3BOUillPEFdacJlAG-YeGgKnaNSsKQQW_G9AwEJeU6HqxqYFX1jwjPnomkWZjxGlrxHI1pxihZeXfbQFTEXIQax-PZ68e3pPBd0zCyHUD-TdbEKFj6_7iuy_f9vf3rOHx7sft18fmO23kplJOc2V6zrlzNDpmU8C9DQMu85sTScGPYmp65UapHYTmEl3vQS9AyMF4lZekS9nrS2p1gLzmItfTDmOgo-n3kbsbXzpDdnPZza3aQH3n_xXlPwLhIebIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T H 1 T-cells</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Marques-Piubelli, Mario L ; Seervai, Riyad N H ; Mudaliar, Kumaran M ; Ma, Wencai ; Milton, Denái R ; Wang, Jing ; Muhlbauer, Aaron ; Parra, Edwin R ; Solis, Luisa M ; Nagarajan, Priyadharsini ; Speiser, Jodi ; Hudgens, Courtney ; Cho, Woo Cheal ; Aung, Phyu P ; Patel, Anisha ; Pacha, Omar ; Nelson, Kelly C ; Tetzlaff, Michael T ; Amaria, Rodabe N ; Torres-Cabala, Carlos A ; Prieto, Victor G ; Wistuba, Ignacio I ; Curry, Jonathan L</creator><creatorcontrib>Marques-Piubelli, Mario L ; Seervai, Riyad N H ; Mudaliar, Kumaran M ; Ma, Wencai ; Milton, Denái R ; Wang, Jing ; Muhlbauer, Aaron ; Parra, Edwin R ; Solis, Luisa M ; Nagarajan, Priyadharsini ; Speiser, Jodi ; Hudgens, Courtney ; Cho, Woo Cheal ; Aung, Phyu P ; Patel, Anisha ; Pacha, Omar ; Nelson, Kelly C ; Tetzlaff, Michael T ; Amaria, Rodabe N ; Torres-Cabala, Carlos A ; Prieto, Victor G ; Wistuba, Ignacio I ; Curry, Jonathan L</creatorcontrib><description>Immune checkpoint inhibitor (ICI)-based cancer therapies cause a variety of cutaneous immune-related adverse events (irAEs) including immunobullous skin eruptions like bullous pemphigoid (BP). However, little is known about the underlying immunopathogenic drivers of these reactions, and understanding the unique gene expression profile and immune composition of BP-irAE remains a critical knowledge gap in the field of oncodermatology/oncodermatopathology. BP-irAE (n = 8) and de novo BP control (n = 8) biopsy samples were subjected to gene expression profiling using the NanoString® Technologies nCounter PanCancer Immune Profiling Panel. Multiplex immunofluorescence (mIF) studies using markers for T-cells (CD3 and CD8), T helper 1 (T 1) cells (Tbet), T 2 cells (Gata3), T 17 cells (RORγT), and regulatory T-cells (Tregs; FoxP3) were further evaluated using InForm® image analysis. Compared with de novo BP controls, BP-irAE samples exhibited upregulation of 30 mRNA transcripts (p &lt; 0.025), including toll-like receptor 4 (TLR4) and genes associated with complement activation, and downregulation of 89 mRNA transcripts (p &lt; 0.025), including genes associated with T 2, T 17, and B-cell immune response. BP-irAE demonstrated a greater density of Tbet (T 1) cells in the dermis (p = 0.004) and fewer Tregs in the blister floor (p = 0.028) when compared with that of de novo control BP samples. BP-irAE exhibited activation of the TLR4/complement-driven classical innate immune response pathway, with dermal T 1 immune cell polarization and decreased Tregs in the blister floor. TLR/complement signaling may underlie the immunopathogenesis of BP-irAE.</description><identifier>ISSN: 0303-6987</identifier><identifier>EISSN: 1600-0560</identifier><identifier>DOI: 10.1111/cup.14442</identifier><identifier>PMID: 37150813</identifier><language>eng</language><publisher>United States</publisher><ispartof>Journal of cutaneous pathology, 2023-07, Vol.50 (7), p.661-673</ispartof><rights>2023 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c573-ab4d604d224da826f0b1e6b8892a7a2186b1b2544836dbeab6253e69ea31826c3</cites><orcidid>0000-0002-3398-0573 ; 0000-0002-6324-2096 ; 0000-0001-9204-7161 ; 0000-0003-0630-6222 ; 0000-0001-5867-1403 ; 0000-0002-0736-9076 ; 0000-0001-7422-0661 ; 0000-0001-7210-8350 ; 0000-0002-5346-2669</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37150813$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marques-Piubelli, Mario L</creatorcontrib><creatorcontrib>Seervai, Riyad N H</creatorcontrib><creatorcontrib>Mudaliar, Kumaran M</creatorcontrib><creatorcontrib>Ma, Wencai</creatorcontrib><creatorcontrib>Milton, Denái R</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Muhlbauer, Aaron</creatorcontrib><creatorcontrib>Parra, Edwin R</creatorcontrib><creatorcontrib>Solis, Luisa M</creatorcontrib><creatorcontrib>Nagarajan, Priyadharsini</creatorcontrib><creatorcontrib>Speiser, Jodi</creatorcontrib><creatorcontrib>Hudgens, Courtney</creatorcontrib><creatorcontrib>Cho, Woo Cheal</creatorcontrib><creatorcontrib>Aung, Phyu P</creatorcontrib><creatorcontrib>Patel, Anisha</creatorcontrib><creatorcontrib>Pacha, Omar</creatorcontrib><creatorcontrib>Nelson, Kelly C</creatorcontrib><creatorcontrib>Tetzlaff, Michael T</creatorcontrib><creatorcontrib>Amaria, Rodabe N</creatorcontrib><creatorcontrib>Torres-Cabala, Carlos A</creatorcontrib><creatorcontrib>Prieto, Victor G</creatorcontrib><creatorcontrib>Wistuba, Ignacio I</creatorcontrib><creatorcontrib>Curry, Jonathan L</creatorcontrib><title>Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T H 1 T-cells</title><title>Journal of cutaneous pathology</title><addtitle>J Cutan Pathol</addtitle><description>Immune checkpoint inhibitor (ICI)-based cancer therapies cause a variety of cutaneous immune-related adverse events (irAEs) including immunobullous skin eruptions like bullous pemphigoid (BP). However, little is known about the underlying immunopathogenic drivers of these reactions, and understanding the unique gene expression profile and immune composition of BP-irAE remains a critical knowledge gap in the field of oncodermatology/oncodermatopathology. BP-irAE (n = 8) and de novo BP control (n = 8) biopsy samples were subjected to gene expression profiling using the NanoString® Technologies nCounter PanCancer Immune Profiling Panel. Multiplex immunofluorescence (mIF) studies using markers for T-cells (CD3 and CD8), T helper 1 (T 1) cells (Tbet), T 2 cells (Gata3), T 17 cells (RORγT), and regulatory T-cells (Tregs; FoxP3) were further evaluated using InForm® image analysis. Compared with de novo BP controls, BP-irAE samples exhibited upregulation of 30 mRNA transcripts (p &lt; 0.025), including toll-like receptor 4 (TLR4) and genes associated with complement activation, and downregulation of 89 mRNA transcripts (p &lt; 0.025), including genes associated with T 2, T 17, and B-cell immune response. BP-irAE demonstrated a greater density of Tbet (T 1) cells in the dermis (p = 0.004) and fewer Tregs in the blister floor (p = 0.028) when compared with that of de novo control BP samples. BP-irAE exhibited activation of the TLR4/complement-driven classical innate immune response pathway, with dermal T 1 immune cell polarization and decreased Tregs in the blister floor. TLR/complement signaling may underlie the immunopathogenesis of BP-irAE.</description><issn>0303-6987</issn><issn>1600-0560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo9kbFuFDEQhi0EIpdAwQsgtxRO7LXXt1eiCBKkSGmuX3nt2cPgtS17HeWemxdgLheYZppvvn-kn5BPgl8LnBvb8rVQSnVvyEZozhnvNX9LNlxyyfRu2F6Qy1p_cS70oPv35EJuRc8HITfkzx1EoPCcC9TqU6S5pNkHHw_UREeXFlafAzxTvywtpjm0hKSFaAEBE47VV5pmOrUQUqs0w5J_-kPy7nwBrEAwKzhq3BOUillPEFdacJlAG-YeGgKnaNSsKQQW_G9AwEJeU6HqxqYFX1jwjPnomkWZjxGlrxHI1pxihZeXfbQFTEXIQax-PZ68e3pPBd0zCyHUD-TdbEKFj6_7iuy_f9vf3rOHx7sft18fmO23kplJOc2V6zrlzNDpmU8C9DQMu85sTScGPYmp65UapHYTmEl3vQS9AyMF4lZekS9nrS2p1gLzmItfTDmOgo-n3kbsbXzpDdnPZza3aQH3n_xXlPwLhIebIQ</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Marques-Piubelli, Mario L</creator><creator>Seervai, Riyad N H</creator><creator>Mudaliar, Kumaran M</creator><creator>Ma, Wencai</creator><creator>Milton, Denái R</creator><creator>Wang, Jing</creator><creator>Muhlbauer, Aaron</creator><creator>Parra, Edwin R</creator><creator>Solis, Luisa M</creator><creator>Nagarajan, Priyadharsini</creator><creator>Speiser, Jodi</creator><creator>Hudgens, Courtney</creator><creator>Cho, Woo Cheal</creator><creator>Aung, Phyu P</creator><creator>Patel, Anisha</creator><creator>Pacha, Omar</creator><creator>Nelson, Kelly C</creator><creator>Tetzlaff, Michael T</creator><creator>Amaria, Rodabe N</creator><creator>Torres-Cabala, Carlos A</creator><creator>Prieto, Victor G</creator><creator>Wistuba, Ignacio I</creator><creator>Curry, Jonathan L</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-3398-0573</orcidid><orcidid>https://orcid.org/0000-0002-6324-2096</orcidid><orcidid>https://orcid.org/0000-0001-9204-7161</orcidid><orcidid>https://orcid.org/0000-0003-0630-6222</orcidid><orcidid>https://orcid.org/0000-0001-5867-1403</orcidid><orcidid>https://orcid.org/0000-0002-0736-9076</orcidid><orcidid>https://orcid.org/0000-0001-7422-0661</orcidid><orcidid>https://orcid.org/0000-0001-7210-8350</orcidid><orcidid>https://orcid.org/0000-0002-5346-2669</orcidid></search><sort><creationdate>202307</creationdate><title>Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T H 1 T-cells</title><author>Marques-Piubelli, Mario L ; Seervai, Riyad N H ; Mudaliar, Kumaran M ; Ma, Wencai ; Milton, Denái R ; Wang, Jing ; Muhlbauer, Aaron ; Parra, Edwin R ; Solis, Luisa M ; Nagarajan, Priyadharsini ; Speiser, Jodi ; Hudgens, Courtney ; Cho, Woo Cheal ; Aung, Phyu P ; Patel, Anisha ; Pacha, Omar ; Nelson, Kelly C ; Tetzlaff, Michael T ; Amaria, Rodabe N ; Torres-Cabala, Carlos A ; Prieto, Victor G ; Wistuba, Ignacio I ; Curry, Jonathan L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573-ab4d604d224da826f0b1e6b8892a7a2186b1b2544836dbeab6253e69ea31826c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marques-Piubelli, Mario L</creatorcontrib><creatorcontrib>Seervai, Riyad N H</creatorcontrib><creatorcontrib>Mudaliar, Kumaran M</creatorcontrib><creatorcontrib>Ma, Wencai</creatorcontrib><creatorcontrib>Milton, Denái R</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Muhlbauer, Aaron</creatorcontrib><creatorcontrib>Parra, Edwin R</creatorcontrib><creatorcontrib>Solis, Luisa M</creatorcontrib><creatorcontrib>Nagarajan, Priyadharsini</creatorcontrib><creatorcontrib>Speiser, Jodi</creatorcontrib><creatorcontrib>Hudgens, Courtney</creatorcontrib><creatorcontrib>Cho, Woo Cheal</creatorcontrib><creatorcontrib>Aung, Phyu P</creatorcontrib><creatorcontrib>Patel, Anisha</creatorcontrib><creatorcontrib>Pacha, Omar</creatorcontrib><creatorcontrib>Nelson, Kelly C</creatorcontrib><creatorcontrib>Tetzlaff, Michael T</creatorcontrib><creatorcontrib>Amaria, Rodabe N</creatorcontrib><creatorcontrib>Torres-Cabala, Carlos A</creatorcontrib><creatorcontrib>Prieto, Victor G</creatorcontrib><creatorcontrib>Wistuba, Ignacio I</creatorcontrib><creatorcontrib>Curry, Jonathan L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of cutaneous pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marques-Piubelli, Mario L</au><au>Seervai, Riyad N H</au><au>Mudaliar, Kumaran M</au><au>Ma, Wencai</au><au>Milton, Denái R</au><au>Wang, Jing</au><au>Muhlbauer, Aaron</au><au>Parra, Edwin R</au><au>Solis, Luisa M</au><au>Nagarajan, Priyadharsini</au><au>Speiser, Jodi</au><au>Hudgens, Courtney</au><au>Cho, Woo Cheal</au><au>Aung, Phyu P</au><au>Patel, Anisha</au><au>Pacha, Omar</au><au>Nelson, Kelly C</au><au>Tetzlaff, Michael T</au><au>Amaria, Rodabe N</au><au>Torres-Cabala, Carlos A</au><au>Prieto, Victor G</au><au>Wistuba, Ignacio I</au><au>Curry, Jonathan L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T H 1 T-cells</atitle><jtitle>Journal of cutaneous pathology</jtitle><addtitle>J Cutan Pathol</addtitle><date>2023-07</date><risdate>2023</risdate><volume>50</volume><issue>7</issue><spage>661</spage><epage>673</epage><pages>661-673</pages><issn>0303-6987</issn><eissn>1600-0560</eissn><abstract>Immune checkpoint inhibitor (ICI)-based cancer therapies cause a variety of cutaneous immune-related adverse events (irAEs) including immunobullous skin eruptions like bullous pemphigoid (BP). However, little is known about the underlying immunopathogenic drivers of these reactions, and understanding the unique gene expression profile and immune composition of BP-irAE remains a critical knowledge gap in the field of oncodermatology/oncodermatopathology. BP-irAE (n = 8) and de novo BP control (n = 8) biopsy samples were subjected to gene expression profiling using the NanoString® Technologies nCounter PanCancer Immune Profiling Panel. Multiplex immunofluorescence (mIF) studies using markers for T-cells (CD3 and CD8), T helper 1 (T 1) cells (Tbet), T 2 cells (Gata3), T 17 cells (RORγT), and regulatory T-cells (Tregs; FoxP3) were further evaluated using InForm® image analysis. Compared with de novo BP controls, BP-irAE samples exhibited upregulation of 30 mRNA transcripts (p &lt; 0.025), including toll-like receptor 4 (TLR4) and genes associated with complement activation, and downregulation of 89 mRNA transcripts (p &lt; 0.025), including genes associated with T 2, T 17, and B-cell immune response. BP-irAE demonstrated a greater density of Tbet (T 1) cells in the dermis (p = 0.004) and fewer Tregs in the blister floor (p = 0.028) when compared with that of de novo control BP samples. BP-irAE exhibited activation of the TLR4/complement-driven classical innate immune response pathway, with dermal T 1 immune cell polarization and decreased Tregs in the blister floor. TLR/complement signaling may underlie the immunopathogenesis of BP-irAE.</abstract><cop>United States</cop><pmid>37150813</pmid><doi>10.1111/cup.14442</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3398-0573</orcidid><orcidid>https://orcid.org/0000-0002-6324-2096</orcidid><orcidid>https://orcid.org/0000-0001-9204-7161</orcidid><orcidid>https://orcid.org/0000-0003-0630-6222</orcidid><orcidid>https://orcid.org/0000-0001-5867-1403</orcidid><orcidid>https://orcid.org/0000-0002-0736-9076</orcidid><orcidid>https://orcid.org/0000-0001-7422-0661</orcidid><orcidid>https://orcid.org/0000-0001-7210-8350</orcidid><orcidid>https://orcid.org/0000-0002-5346-2669</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0303-6987
ispartof Journal of cutaneous pathology, 2023-07, Vol.50 (7), p.661-673
issn 0303-6987
1600-0560
language eng
recordid cdi_crossref_primary_10_1111_cup_14442
source Wiley Online Library Journals Frontfile Complete
title Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T H 1 T-cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T01%3A17%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gene%20expression%20profiling%20and%20multiplex%20immunofluorescence%20analysis%20of%20bullous%20pemphigoid%20immune-related%20adverse%20event%20reveal%20upregulation%20of%20toll-like%20receptor%204/complement-induced%20innate%20immune%20response%20and%20increased%20density%20of%20T%20H%201%20T-cells&rft.jtitle=Journal%20of%20cutaneous%20pathology&rft.au=Marques-Piubelli,%20Mario%20L&rft.date=2023-07&rft.volume=50&rft.issue=7&rft.spage=661&rft.epage=673&rft.pages=661-673&rft.issn=0303-6987&rft.eissn=1600-0560&rft_id=info:doi/10.1111/cup.14442&rft_dat=%3Cpubmed_cross%3E37150813%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37150813&rfr_iscdi=true